LEUKEMIA THERAPEUTICS MARKET ANALYSIS
Moreover rising product approval and product launch by the market players is expected to propel the leukemia therapeutics market. For instance, in November 2018, Pfizer Inc., received the U.S. Food and Drug Administration (FDA) approval for glasdegib (DAURISMO), the Hedgehog pathway inhibitor for the treatment of adults suffering from acute myeloid leukemia (AML). Similarly, in April 2017, Novartis Pharmaceuticals, Inc., received U.S. Food and Drug Administration (FDA) approval for midostaurin (Rydapt) for the treatment of adult diagnosed with FLT3-mutated acute myeloid leukemia (AML).
Need a Custom Report?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now
Credibility and Certifications
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
U.S.: 
U.K. : 
India : 